You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

70 search results for: coexisting diseases

What proportion of patients can achieve control in CRSwNP?
expert video

What proportion of patients can achieve control in CRSwNP?

Rhinology
Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.
View more
Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?
interactivity

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

Dermatology
Gain insights with Prof. Lisa Beck: Explore the link between skin barrier dysfunction and type 2 inflammation in atopic dermatitis.
View more
EAACI 2023 | Recognizing EoE in the Allergy Clinic
expert video

EAACI 2023 | Recognizing EoE in the Allergy Clinic

Gastroenterology
Join Dr. Antonella Cianferoni as she discusses how allergists can help identify EoE patients in the allergy clinic and support patient care.
View more
Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Dermatology
Highlights from the ESPD 2023 ADVENT symposium: Exploring burden and comorbidities associated with moderate-to-severe atopic dermatitis in children.
View more
Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?
expert video

Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?

Dermatology
Highlights from the ESPD 2023 ADVENT symposium, exploring burden, skin barrier normalization, and current treatments for pediatric atopic dermatitis.
View more
Early Intervention in AD: Latest Clinical and Real-world Data
expert video

Early Intervention in AD: Latest Clinical and Real-world Data

Dermatology
Highlights from ESPD 2023 ADVENT: Reviewing the current treatment landscape and the potential for early intervention in pediatric atopic dermatitis.
View more
Targeting Type 2 Inflammation: ​Skin Barrier Normalization​
expert video

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​

Dermatology
Highlights from ESPD 2023 ADVENT: Uncovering how type 2 inflammation influences skin barrier dysfunction in atopic dermatitis.
View more
Children and EoE: More Than Just Being a Picky Eater
expert video

Children and EoE: More Than Just Being a Picky Eater

Gastroenterology
Join Prof. Alexandra Papadopoulou as she reviews the multifaceted burden of children with EoE.
View more
EoE Burden and Pathophysiology of Type 2 Inflammation
videoanimation

EoE Burden and Pathophysiology of Type 2 Inflammation

Gastroenterology
Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.
View more
Type 2 Inflammation Underpins Pediatric Severe Asthma
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Pulmonology
Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.
View more
Scientific Advances in EoE and Impact on Clinical Practice
expert video

Scientific Advances in EoE and Impact on Clinical Practice

Gastroenterology
Expert gastroenterologist Dr. Evan Dellon highlights research and scientific advances in EoE and their impact on clinical practice.
View more
Mast Cells and the Neuroimmune Axis in CSU
expert video

Mast Cells and the Neuroimmune Axis in CSU

Dermatology
A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SpainChange country/region